HPV testing and Pap test market: Size, Growth And Market Analysis



Human papillomavirus:

Human papillomavirus or HPVs are called mucosal because they infect live cells on mucosal surfaces. Cervical cancer can be prevented by detecting and treating abnormal cells that grow in the cervix. HPV and Pap tests are the two most popular tests used to examine the activity of cervical cells.


Market Analysis:


From USD 3.29 billion in 2015 to USD 4.52 billion in 2020, the global HPV testing and Pap test market is expected to grow at a CAGR of 6.6 percent. Cervical cancer is the second most frequent cancer in women, coming in second only to breast cancer.

Cervical cancer is caused by HPV, a sexually transmitted virus that has been scientifically confirmed to be the primary cause. Around 90% of all anal and cervical cancers, as well as 70% of vaginal and vulvar cancers, are caused by HPV. Cervical cancer is most commonly detected via Pap testing.


One of these tests is the microscopic examination of specimens. These tests, however, are unable to detect all genotypes that cause HPV infections and may result in a large percentage of false-negative results. HPV diagnostic techniques were introduced as effective molecular diagnostic tests in response to the limitations provided by Pap testing.


The HPV testing and Pap test market is divided into two categories: HPV testing and Pap test. HPV testing is chosen over Pap testing because of its widespread application in cervical cancer screening and growing awareness of the process. The market for HPV testing is divided into three categories: follow-up HPV testing, co-testing, and HPV main testing. During the forecast period, the HPV primary testing sector is predicted to grow at the fastest rate.


Application Based Insights:

The Pap test market is divided into cervical cancer screening and vaginal cancer screening, depending on the application. Due to rising cervical cancer rates, the cervical cancer screening segment is predicted to increase at the fastest CAGR during the forecast period.


End User-Based Insights:

The HPV testing and Pap test market is divided into hospitals, laboratories, physician's offices, and clinics based on the end-user. From 2015 to 2020, the hospital segment is expected to develop at the fastest rate. This increase can be ascribed to rising hospital patient loads, as most diagnostic tests are now performed in-house using improved technologies and with greater accessibility.


Regional Insights:

The market for HPV testing and Pap tests is divided into four regions: North America, Europe, Asia Pacific, and the Rest of the World. During the projected period, North America is predicted to increase at the fastest rate. Increased government financing and grants, as well as the launch of HPV primary tests, are driving the HPV testing and Pap test business in North America forward.


Key Players:


Hologic Inc. (US), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (US), OncoHealth Corporation (US), and Becton, Dickinson, and Company are all major competitors in the HPV testing and Pap test market (U.S.).To maintain their growth in the HPV testing and Pap test industry, these companies use inorganic and organic tactics such as product approvals and licensing agreements, collaborations, and partnerships, expansions, and acquisitions.


Comments

Popular posts from this blog

Significance of EHealth Software And Services

The OKR Software Market Is Estimated To Increase At A CAGR Of 12.60 Percent During The Forecast Period

Broadcast Switchers Market Report | the Demand for the Market Will Drastically Increase in the Future